Novartis Agrees to Acquire Avidity Biosciences
Novartis has entered into an agreement to acquire Avidity Biosciences, Inc., a biopharmaceutical company based in San Diego, focused on RNA delivery to muscle.
Avidity is working on a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs) for serious, genetic neuromuscular diseases.
The acquisition will bring Avidity’s late-stage neuroscience programs into Novartis, providing access to a differentiated RNA-targeting delivery platform.
Novartis acquires Avidity Biosciences to expand its portfolio.
Author's summary: Novartis acquires Avidity Biosciences to expand portfolio.